Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly’s Zepbound in a head-to-head clinical trial.
Source link
About The Author
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial